Kerala Nipah drug row: Minister suspects clinical trial medicine used during Vijayan rule
Synopsis
Kerala's Nipah drug controversy has taken a serious turn: Health Minister K. Muraleedharan now suspects clinical trial-stage medicines — not just expired Remdesivir — were administered to patients during the Pinarayi Vijayan government. With a medical board probing possible links to patient deaths, and foreign pharma intermediaries under the scanner, this is no longer just a procurement lapse story.
Key Takeaways
Kerala Health Minister K.
Muraleedharan alleged on 30 October 2026 that clinical trial medicines may have been given to Nipah patients during the Pinarayi Vijayan government.
Some medicines supplied reportedly lacked manufacturing dates , raising further safety concerns.
KMSCL procured 3,000 vials of Remdesivir on 3 June 2021 at ₹42 lakh ; the drug expired on 30 May 2023 but was reportedly used through 2025-26 .
A medical board headed by Dr R.
Aravind of Thiruvananthapuram Medical College will investigate links between the suspected expired drug use and patient deaths.
The investigation will also examine foreign pharmaceutical companies , intermediaries, and financial transactions involved in the supply.
50 vials used in 2026 were separately procured from Bahrain on 12 June 2026 and are not part of the expired-drug allegation.
Kerala Health Minister K. Muraleedharan on Friday, 30 October 2026, raised fresh concerns over medicines supplied to Nipah patients in the state during the tenure of former Chief Minister Pinarayi Vijayan, alleging that drugs meant for clinical trials may have been administered to patients and that some supplied medicines lacked manufacturing dates. The minister made these remarks while speaking to reporters in Kozhikode, adding that a comprehensive investigation had been ordered.
What the Investigation Will Cover
The probe, ordered on the basis of information provided by the Superintendent of Kozhikode Medical College, will examine foreign pharmaceutical companies involved in the supply of these medicines, the intermediaries who facilitated the transactions, and the financial benefits they received. Muraleedharan said the government would take appropriate action once all facts are established.
The Expired Remdesivir Allegation
The latest development follows the minister's disclosure in the Kerala Assembly on Thursday that Remdesivir purchased in 2021 — with an expiry date of 30 May 2023 — was suspected to have been used in subsequent years. The Kerala Medical Services Corporation (KMSCL) had procured 3,000 vials of the drug on 3 June 2021 at a cost of ₹42 lakh.
According to records from Kozhikode Medical College, 102 vials were used in 2023-24, 34 vials in 2024-25, and 10 vials in 2025-26. Muraleedharan clarified that the 50 vials used in 2026 were separately procured from Bahrain on 12 June 2026 and are therefore not under the same scrutiny.
Medical Board Constituted to Assess Patient Impact
A medical board has been constituted, headed by Dr R. Aravind, Head of the Infectious Diseases Department at Thiruvananthapuram Medical College, to examine whether the suspected use of expired medicines contributed to patient deaths and whether other recipients experienced adverse effects. The board's findings are expected to be a key input for any further legal or administrative action.
Opposition Leader Vijayan's Letter: What It Said
Addressing the political dimension of the controversy, Muraleedharan noted that a letter sent to him by Leader of the Opposition Pinarayi Vijayan — who headed the state from 2016 to 2026 — had only cautioned against giving cheaper medicines to patients. According to the minister, the letter contained no reference to clinical trials or expired drugs, effectively deflecting any suggestion that the opposition had flagged this issue earlier.
Political and Public Health Implications
This controversy sits at the intersection of public health governance and political accountability. Kerala has faced multiple Nipah outbreaks in recent years, and each episode has drawn intense scrutiny over the state's disease-response protocols. Critics argue that if drugs administered during a viral outbreak lacked manufacturing dates or were clinical trial-stage medicines, the oversight failure is serious — regardless of which administration was in power. The investigation's findings could have significant consequences for both the current government's health administration credibility and the legacy of the previous regime.
All eyes are now on the medical board's report and whether the state's health department will refer the matter to central drug regulators.
Point of View
Administering unapproved trial-stage medicines to outbreak patients without proper consent frameworks would be a serious regulatory breach, not merely a paperwork lapse. The investigation's focus on foreign pharma intermediaries and their financial gains also hints at a procurement accountability problem that may extend well beyond Nipah. The current government is right to investigate, but it must guard against turning a genuine public health inquiry into an instrument of political score-settling.
NationPress
30 Oct 2026
Frequently Asked Questions
What is the Kerala Nipah drug row about?
The controversy centres on allegations that medicines supplied to Nipah patients in Kerala during the Pinarayi Vijayan government (2016–2026) may have included drugs meant for clinical trials and vials without manufacturing dates. Health Minister K. Muraleedharan also disclosed that Remdesivir that expired in May 2023 was reportedly used in subsequent years, prompting a formal investigation.
How many Remdesivir vials were procured and at what cost?
The Kerala Medical Services Corporation (KMSCL) purchased 3,000 vials of Remdesivir on 3 June 2021 at a cost of ₹42 lakh. The drug had an expiry date of 30 May 2023, but records show it was used in 2023-24, 2024-25, and 2025-26.
Who is investigating the alleged use of expired and clinical trial medicines?
A medical board headed by Dr R. Aravind, Head of the Infectious Diseases Department at Thiruvananthapuram Medical College, has been constituted. It will examine whether the suspected use of expired medicines was linked to patient deaths and whether other recipients suffered adverse effects.
What did Opposition Leader Pinarayi Vijayan's letter to the minister say?
According to Health Minister Muraleedharan, the letter from Leader of the Opposition Pinarayi Vijayan only cautioned against administering cheaper medicines to patients and made no mention of clinical trial drugs or expired medicines.
What happens next in the investigation?
The probe will examine foreign pharmaceutical companies involved in the supply, intermediaries who facilitated transactions, and any financial benefits they received. The government has said it will take appropriate action once the investigation establishes all the facts.
